Pirfenidone (Esbriet) prior authorization at UnitedHealthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UnitedHealthcare requires prior-authorization documentation for Pirfenidone (Esbriet): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
UnitedHealthcare reviews Pirfenidone (Esbriet) prior authorizations against its medical policy . UnitedHealthcare-specific context: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UnitedHealthcare's medical policy URL referenced in the cover letter
UnitedHealthcare's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- GLP-1 weight-loss exclusion
- Out-of-network reduction citing UCR
- Step therapy on biologics
- Prior auth denied for advanced imaging
- Quantity limits on specialty drugs
Pirfenidone (Esbriet)-specific denial patterns and context
Across payers (not just UnitedHealthcare), Pirfenidone (Esbriet)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- FVC threshold requirements (plan demands 50-80% predicted)
- Step therapy requiring nintedanib first
- Liver function monitoring not documented
- Confirmation of IPF diagnosis by HRCT + multidisciplinary review
Brand: Esbriet. Antifibrotic for IPF. Multiple generics available since 2022. Photosensitivity warning. CAPACITY and ASCEND trial program.
Manufacturer patient-assistance program: Genentech Access Solutions — relevant when a UnitedHealthcare denial sticks and the patient needs bridge access while appealing.
How UnitedHealthcare approaches Antifibrotic agents PAs
UnitedHealthcare's Antifibrotic agents reviewer typically anchors Pirfenidone prior-auth decisions on step therapy on biologics and quantity limits on specialty drugs. Pharmacy-benefit review for Pirfenidone at UnitedHealthcare is routed through OptumRx (in-house PBM, parent UnitedHealth Group). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. UnitedHealthcare's FVC-threshold restrictions are increasingly out of step with ATS/ERS/JRS/ALAT 2022 guidance, which recommends antifibrotic initiation regardless of FVC band. UnitedHealthcare is domiciled in MN, so unresolved appeals escalate to the MN insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest.
If the PA is denied
UnitedHealthcare gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.uhcprovider.com) with the same packet plus a peer-reviewed citation supporting Pirfenidone (Esbriet)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a UnitedHealthcare denial on DenialHelp.
Contact UnitedHealthcare
- Provider portal: https://www.uhcprovider.com
Frequently asked questions
What documentation does UnitedHealthcare need for Pirfenidone (Esbriet) prior auth?
UnitedHealthcare's typical PA packet for Pirfenidone (Esbriet): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at UnitedHealthcare?
Standard Pirfenidone (Esbriet) PA decisions at UnitedHealthcare: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does UnitedHealthcare most often reject Pirfenidone (Esbriet) for?
Across UnitedHealthcare's book the common rejection patterns include: GLP-1 weight-loss exclusion; Out-of-network reduction citing UCR; Step therapy on biologics. For Pirfenidone (Esbriet) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Does UnitedHealthcare's FVC threshold for Pirfenidone match current ATS guidance?
Many UnitedHealthcare antifibrotic policies require FVC 50-80% predicted, but the 2022 ATS/ERS/JRS/ALAT IPF guideline recommends antifibrotic initiation regardless of FVC band — citing this guidance in appeals frequently overturns FVC-threshold denials. Attach the HRCT report with UIP or probable-UIP pattern, multidisciplinary discussion documentation, and the specific FVC value with rate of decline if available. Pharmacy-benefit handling is routed through OptumRx (in-house PBM, parent UnitedHealth Group). External-review escalation for UnitedHealthcare fully-insured policies sits with the MN insurance department.
How do I prep for a peer-to-peer with UnitedHealthcare on Pirfenidone (Esbriet)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Pirfenidone (Esbriet) PA packet
Open ApprovalHelp — generate a Pirfenidone (Esbriet) prior-auth packet tailored to UnitedHealthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com